Sun Pharma net down 60%

Led by disappointing sales in the US market, drug major Sun Pharmaceutical Industries’ consolidated net profit fell 60 per cent to Rs 912.12 crore for the September 2017 quarter, against Rs 2,235.14 c

Published: 15th November 2017 03:08 AM  |   Last Updated: 15th November 2017 08:37 AM   |  A+A-

By Express News Service

MUMBAI: Led by disappointing sales in the US market, drug major Sun Pharmaceutical Industries’ consolidated net profit fell 60 per cent to Rs 912.12 crore for the September 2017 quarter, against Rs 2,235.14 crore in the year-ago period.

Total revenue from operations, too, was lower at Rs 6,650.34 crore compared with Rs 8,260.11 crore.
Sales in the US stood fell 44 per cent at $309 million.

It accounts for 30 per cent of Sun’s total sales. According to Dilip Shanghvi, MD, Sun Pharma, a challenging US generic pricing environment coupled with continued investments in building its global speciality business impacted the firm’s second quarter performance, but it hopes to better the performance in the second half of the current fiscal.

Stay up to date on all the latest Business news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

facebook twitter whatsapp